FLT3 and acute myeloid leukemia: NC525-mediated AML suppression was observed across multiple donors and AML subtypes, including normal-karyotype AML, monocytic AML, acute myelomonocytic leukemia (AMML), FLT3-ITD+ AML, and uncharacterized AML (Figure 3B).